

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **APPROVAL FOR MARKETING OF THE GROUP'S PRODUCT TADALAFIL TABLETS**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the applications for marketing of Tadalafil Tablets (specifications: 5mg; 10mg; 20mg) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the Company, have been approved by China National Medical Products Administration with National Drug Approval Numbers H20265009, H20265010 and H20265011 respectively.

Tadalafil Tablets are a selective phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction and erectile dysfunction associated with benign prostatic hyperplasia. Compared with other drugs in the same class, their key advantage lies in a prolonged duration of action of up to 36 hours and efficacy that is not affected by food intake, providing patients with greater flexibility in treatment and expanding their clinical value.

The approval of Tadalafil Tablets further enriches the Company's diversified product portfolio and is expected to enhance its market competitiveness and brand influence in men's health sector. Looking ahead, the Company will continue to invest in the research and development of new products, strengthen its competitiveness and innovation capabilities in the pharmaceutical industry, which is expected to create greater values for the Company and its shareholders.

By Order of the Board

**The United Laboratories International Holdings Limited**

**Tsoi Hoi Shan**

*Chairman*

Hong Kong, 2 July 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.